Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors Meeting Abstract
| Authors: | Papadopoulos, K. P.; Autio, K. A.; Golan, T.; Dobrenkov, K.; Chartash, E.; Li, X. N.; Wnek, R.; Long, G. V. |
| Abstract Title: | Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 510s |
| Language: | English |
| ACCESSION: | WOS:000487345806563 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.9509 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9509 -- Source: Wos |
